Patients with moderate-to-severe atopic dermatitis contend with relentless skin inflammation and a parallel psychological burden—yet treatment often targets one domain at the expense of the other.
At the XIV International Congress of Dermatology (ICD 2025), real-world data supporting psychological improvement revealed that lebrikizumab markedly decreased anxiety and depression scores among AD patients, highlighting its potential to bridge this treatment gap.
While dermatologists have long valued reductions in Eczema Area and Severity Index and itch severity, this evolving evidence underscores that lebrikizumab’s impact extends beyond the skin. Patients treated with lebrikizumab in the registries discussed at the meeting achieved rapid and sustained relief of erythema, pruritus, and lichenification—improvements that correlate with enhanced daily functioning and patient satisfaction.
Insights from the ADvocate trial further reinforce a holistic benefit: alongside substantial symptom improvement in moderate-to-severe AD, participants reported boosted self-esteem and social engagement. This aligns with earlier findings, suggesting a consistent pattern in both clinical trials and practice settings.
Integrating these dual outcomes into practice calls for a recalibration of treatment goals. Dermatologists may now consider routine assessment of psychological well-being when initiating lebrikizumab, collaborating with mental health professionals to optimize patient support. Identifying patient subsets—such as those with documented anxiety or depressive symptoms—could help personalize therapy and monitor response more comprehensively.
Key Takeaways:- Emerging evidence suggests that lebrikizumab offers dual benefits, enhancing both skin health and psychological well-being in AD.
- Recent data from ICD 2025 demonstrates lebrikizumab’s effectiveness in reducing moderate-to-severe AD symptoms.
- Its comprehensive approach represents a shift towards holistic treatment strategies in dermatology.